UCB S.A., a biopharmaceutical enterprise founded in 1925 and headquartered in Brussels, Belgium, focuses on developing innovative solutions for individuals living with neurological and immunological diseases. Its diverse commercialized portfolio includes Cimzia, targeting inflammatory TNF-mediated conditions such as Crohn's disease, various forms of spondyloarthritis, rheumatoid arthritis, and psoriasis. For epilepsy management, UCB offers Vimpat, Keppra, and Briviact, along with Nayzilam, an intranasal rescue treatment for seizure clusters. Neupro is available for Parkinson's disease and restless legs syndrome, while Zyrtec and Xyzal address allergy symptoms. Other key products include Evenity for osteoporosis in postmenopausal women, and BIMZELX, which treats psoriasis, psoriatic arthritis, axial spondyloarthritis, and hidradenitis suppurativa. The company also provides dapirolizumab pegol for systemic lupus erythematosus. UCB's robust development pipeline features candidates like rozanolixizumab, aimed at myasthenia gravis, immune thrombocytopenia, and chronic inflammatory demyelinating polyneuropathy; zilucoplan for myasthenia gravis and immune-mediated necrotizing myopathy; staccato alprazolam for prolonged seizures; Bepranemab for Alzheimer's disease; and UCB0599 for Parkinson's disease. Beyond its proprietary drug development, UCB also conducts contract manufacturing. The company engages in significant collaborations with entities such as Amgen, Biogen, Roche/Genentech, Novartis, Otsuka, and doc.ai. UCB's global footprint extends across numerous countries, including the United States, Japan, China, Belgium, and a broad presence throughout Europe, encompassing Germany, Spain, France, Italy, the United Kingdom, and Ireland.
The current price of UCBJY is $164.04 USD — it has increased by +1% in the past 24 hours. Watch UCB SA stock price performance more closely on the chart.
What is UCB SA stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on OTC Link exchange UCB SA stocks are traded under the ticker UCBJY.
Is UCB SA stock price growing?▼
UCBJY stock has fallen by -2.64% compared to the previous week, the month change is a +43.39% rise, over the last year UCB SA has showed a +24.35% increase.
What is UCB SA market cap?▼
Today UCB SA has the market capitalization of 31.91B
When is the next UCB SA earnings date?▼
UCB SA is going to release the next earnings report on February 25, 2027.
What were UCB SA earnings last quarter?▼
UCBJY earnings for the last quarter are 7.81 USD per share, whereas the estimation was 5.81 USD resulting in a +34.51% surprise. The estimated earnings for the next quarter are N/A USD per share.
What is UCB SA revenue for the last year?▼
UCB SA revenue for the last year amounts to 8.69B USD.
What is UCB SA net income for the last year?▼
UCBJY net income for the last year is 1.83B USD.
Does UCB SA pay dividends?▼
Yes, UCBJY dividends are paid annual. The last dividend per share was 0.85 . As of today, Dividend Yield (FWD)% is 0.52%.
How many employees does UCB SA have?▼
As of November 16, 2026, the company has 9,000 employees.